Physician profile
Mark A Bartz
NPI 1447300173
$1,165.05
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $259 · 2021: $275 · 2022: $229.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $296.29 | 2019-2022 | |
| Lilly USA, LLC | $196.84 | 2019-2022 | |
| Amarin Pharma, INC. | $126.00 | 2019-2022 | |
| Amgen INC. | $89.11 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $66.11 | 2019-2021 | |
| Abbvie INC. | $43.81 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $43.33 | 2020-2021 | |
| Allergan, INC. | $42.05 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $41.89 | 2019 | |
| Sanofi-Aventis U.S. LLC | $39.64 | 2019-2021 | |
| Insulet Corporation | $33.12 | 2019-2021 | |
| Dexcom, INC. | $30.13 | 2022 | |
| Arbor Pharmaceuticals, INC. | $25.69 | 2019 | |
| Pfizer INC. | $24.74 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $24.70 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $15.34 | 2022 | |
| Glaxosmithkline, LLC. | $14.29 | 2022 | |
| Astellas Pharma US INC | $11.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.